Treating Muscular Dystrophy with a Self-Complementary AAV Gene Therapy

This patent describes a method to treat muscular dystrophy by delivering a specific gene using a specially designed, self-complementary adeno-associated virus (AAV) vector.

What it covers

This patent describes methods for treating muscular dystrophy by introducing a specific gene into a patient's cells. It uses a self-complementary recombinant adeno-associated virus (rAAV) vector, specifically named scAAVrh74.tMCK.hSGCA, as a delivery vehicle. This vector is designed to express the alpha-sarcoglycan gene (hSGCA) in the patient's body, which is crucial for muscle function. The patent also covers ways to create this rAAV and pharmaceutical mixtures containing it. For example, a patient with a type of muscular dystrophy caused by a faulty alpha-sarcoglycan gene could receive this vector to help their muscles produce the correct protein.

What it doesn't cover

• —Does not cover gene therapies for muscular dystrophy that use different AAV serotypes (like AAV9 or AAV8) instead of the specified scAAVrh74 vector.
• —Does not cover gene therapies for muscular dystrophy that deliver genes other than alpha-sarcoglycan (hSGCA), such as the dystrophin gene for Duchenne muscular dystrophy.
• —Does not cover non-viral methods of gene delivery, such as lipid nanoparticles or electroporation, for treating muscular dystrophy.
• —Does not cover treatments for muscular dystrophy that do not involve gene therapy, such as physical therapy or steroid medications.
• —Does not cover the use of this specific scAAVrh74.tMCK.hSGCA vector for treating diseases other than muscular dystrophy.

The clever bit

The novelty lies in using a 'self-complementary' AAV vector, which means the viral DNA can quickly form a double-stranded template inside the cell. This speeds up gene expression compared to traditional AAVs, making the therapy potentially more effective and faster-acting for muscle diseases where rapid protein production is critical.

Why it matters

Muscular dystrophy is a group of genetic diseases that cause progressive weakness and loss of muscle mass, often leading to severe disability. Gene therapy offers a promising approach to correct the underlying genetic defects, potentially slowing or halting disease progression. This patent focuses on a specific gene and delivery method, contributing to the development of targeted treatments for these debilitating conditions.

Real-world examples

• 1.Gene therapies for Limb-Girdle Muscular Dystrophy (LGMD)
• 2.Investigational gene therapies targeting sarcoglycan deficiencies
• 3.Sarepta Therapeutics' gene therapy programs for muscular dystrophies